ADA Scientific Sessions 2025 Abstract

Study on the Efficacy and Safety of Henagliflozin Combined with Continuous Subcutaneous Insulin Infusion in the Treatment of Type 2 Diabetes—A Multicenter, Randomized, Open-Label, Controlled Study

By Zhiqiang Huang, Yingling Wu, Chaoyan Tang, Yingfen Qin

Trial in peopleInterventions

The paper

Zhiqiang Huang, Yingling Wu, Chaoyan Tang, Yingfen Qin

Yulin

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 899-P

doi.org/10.2337/db25-899-p

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk